Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Global Antimicrobial Resistance Année : 2021

Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review

Johan Courjon
  • Fonction : Auteur
  • PersonId : 1106956
Pascal Chavanet
  • Fonction : Auteur

Résumé

OBJECTIVES: Dalbavancin is a long-lasting lipoglycopeptide active against Gram-positive bacteria, especially methicillin-resistant staphylococci. Few data are available on dalbavancin use for treatment of prosthetic joint infections (PJIs). We describe a cohort of patients treated for PJI with dalbavancin and review the literature regarding this condition. METHODS: All adult patients with PJI from the French dalbavancin national cohort from 1 June 2017 to 1 January 2019 were included. We collected clinical and microbiological characteristics and outcome through a standardised questionnaire. Clinical cure was defined as absence of clinical signs of infection at last visit. Failure was a composite criterion defined by persistence or reappearance of signs of infection, and/or switch to suppressive antibiotic treatment and/or death from infection. The literature review was performed using PubMed. RESULTS: Seventeen patients were included. Bacteria were identified in 16 cases: Staphylococcus aureus (n = 10), including methicillin-resistant S. aureus (n = 1); and coagulase-negative staphylococci (n = 10), including methicillin-resistant Staphylococcus epidermidis (n = 4). Sixteen patients (94.1%) had received antibiotic therapy prior to dalbavancin use (mean of 2.2 ± 1.3 lines). Clinical cure was achieved in 8/17 patients after a median follow-up of 299.0 (IQR 97.0-476.0) days. We reviewed all cases of PJI treated with dalbavancin available in the literature and the overall clinical cure was estimated at 73.1%. CONCLUSION: Our study and literature data suggest that use of dalbavancin in PJI could be considered, even as salvage therapy. Dalbavancin appears to be a safe and easy treatment for patients with staphylococcal PJIs.
Fichier principal
Vignette du fichier
Matt.pdf (309.62 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03372914 , version 2 (02-06-2022)
hal-03372914 , version 1 (19-04-2024)

Licence

Identifiants

Citer

Morgan Matt, Clara Duran, Johan Courjon, Romain Lotte, Vincent Le Moing, et al.. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. Journal of Global Antimicrobial Resistance, 2021, 25, pp.341-345. ⟨10.1016/j.jgar.2021.03.026⟩. ⟨hal-03372914v2⟩
35 Consultations
96 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More